New insights into the mechanisms of activin action and inhibition

Molecular and Cellular Endocrinology

Volumn 359, Issue 1-2, 2012, Pages 2-12

  Walton, Kelly L ^a   Makanji, Yogeshwar ^a   Harrison, Craig A ^a  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Activin; Betaglycan; Follistatin; Inhibin; Prodomain; Transforming growth factor

Indexed keywords

ACTIVIN; ACTIVIN A; ACTIVIN RECEPTOR 1; ACTIVIN RECEPTOR 2; FOLLISTATIN; GROWTH FACTOR RECEPTOR; INHIBIN; MYELOPID; PROTEOHEPARAN SULFATE; SERINE PROTEINASE; SERINE THREONINE KINASE TYPE II RECEPTOR A; SERINE THREONINE KINASE TYPE II RECEPTOR B; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; COVALENT BOND; CRYSTAL STRUCTURE; DIMERIZATION; HORMONAL REGULATION; HORMONE ACTION; HORMONE INHIBITION; HORMONE RECEPTOR INTERACTION; HORMONE RELEASE; HORMONE STRUCTURE; HORMONE SYNTHESIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN CARBOHYDRATE INTERACTION; PROTEIN CLEAVAGE; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN LOCALIZATION; REVIEW; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION;

ACTIVIN RECEPTORS, TYPE I; ACTIVIN RECEPTORS, TYPE II; ACTIVINS; AMINO ACID MOTIFS; ANIMALS; HUMANS; INHIBINS; PROTEIN BINDING; PROTEIN PRECURSORS; PROTEIN STRUCTURE, TERTIARY; PROTEOGLYCANS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION;

EID: 84861681431     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2011.06.030     Document Type: Review

References (131)

1. Allen D.L., Cleary A.S., Speaker K.J., Lindsay S.F., Uyenishi J., Reed J.M., Madden M.C., Mehan R.S. Myostatin, activin receptor IIb, and follistatin-like-3 gene expression are altered in adipose tissue and skeletal muscle of obese mice. Am. J. Physiol. Endocrinol. Metab. 2008, 294:E918-E927.
2. Allendorph G.P., Vale W.W., Choe S. Structure of the ternary signaling complex of a TGF-beta superfamily member. Proc. Natl. Acad. Sci. USA 2006, 103(20):7643-7648.
3. Andersson O., Reissmann E., Ibáñez C.F. Growth differentiation factor 11 signals through the transforming growth factor-beta receptor ALK5 to regionalize the anterior-posterior axis. EMBO 2006, 7(8):831-837.
4. Andres J.L., Stanley K., Cheifetz S., Massague J. Membrane-anchored and soluble forms of betaglycan, a polymorphic proteoglycan that binds transforming growth factor-beta. J. Cell Biol. 1989, 109:3137-3145.
5. Antenos M., Stemler M., Boime I., Woodruff T.K. N-linked oligosaccharides direct the differential assembly and secretion of inhibin alpha- and betaA-subunit dimers. Mol. Endocrinol. 2007, 21:1670-1684.
6. Antenos M., Zhu J., Jetly N.M., Woodruff T.K. An activin/furin regulatory loop modulates the processing and secretion of inhibin alpha- and betaB-subunit dimers in pituitary gonadotrope cells. J. Biol. Chem. 2008, 283:33059-33068.
7. Arai K.Y., Ohshima K., Watanabe G., Arai K., Uehara K., Taya K. Dynamics of messenger RNAs encoding inhibin/activin subunits and follistatin in the ovary during the rat estrous cycle. Biol. Reprod. 2002, 66:1119-1126.
8. Attisano L., Wrana J.L., Cheifetz S., Massague J. Novel activin receptors: distinct genes and alternative mRNA splicing generate a repertoire of serine/threonine kinase receptors. Cell 1992, 68:97-108.
9. Attisano L., Carcamo J., Ventura F., Weis F.M., Massague J., Wrana J.L. Identification of human activin and TGF beta type I receptors that form heteromeric kinase complexes with type II receptors. Cell 1993, 75:671-680.
10. Attisano L., Wrana J.L. Signal transduction by members of the transforming growth factor-beta superfamily. Cytokine Growth Factor Rev. 1996, 7:327-339.
11. Bernard D.J. Both SMAD2 and SMAD3 mediate activin-stimulated expression of the follicle-stimulating hormone beta subunit in mouse gonadotrope cells. Mol. Endocrinol. 2004, 18:606-623.
12. Bernard D.J., Lee K.B., Santos M.M. Activin B can signal through both ALK4 and ALK7 in gonadotrope cells. Reprod. Biol. Endocrinol. 2006, 4:52.
13. Besecke L.M., Guendner M.J., Sluss P.A., Polak A.G., Woodruff T.K., Jameson J.L., Bauer-Dantoin A.C., Weiss J. Pituitary follistatin regulates activin-mediated production of follicle-stimulating hormone during the rat estrous cycle. Endocrinology 1997, 138:2841-2848.
14. Bilezikjian L.M., Blount A.L., Leal A.M., Donaldson C.J., Fischer W.H., Vale W.W. Autocrine/paracrine regulation of pituitary function by activin, inhibin and follistatin. Mol. Cell. Endocrinol. 2004, 225:29-36.
15. Bondestam J., Huotari M.A., Moren A., Ustinov J., Kaivo-Oja N., Kallio J., Horelli-Kuitunen N., Aaltonen J., Fujii M., Moustakas A., Ten Dijke P., Otonkoski T., Ritvos O. CDNA cloning, expression studies and chromosome mapping of human type I serine/threonine kinase receptor ALK7 (ACVR1C). Cytogenet. Cell Genet. 2001, 95:157-162.
16. Bork P., Sander C. A large domain common to sperm receptors (Zp2 and Zp3) and TGF-beta type III receptor. FEBS Lett. 1992, 300:237-240.
17. Bottinger E.P., Factor V.M., Tsang M.L., Weatherbee J.A., Kopp J.B., Qian S.W., Wakefield L.M., Roberts A.B., Thorgeirsson S.S., Sporn M.B. The recombinant proregion of transforming growth factor beta1 (latency-associated peptide) inhibits active transforming growth factor beta1 in transgenic mice. Proc. Natl. Acad. Sci. USA 1996, 93:5877-5882.
18. Brown C.W., Houston-Hawkins D.E., Woodruff T.K., Matzuk M.M. Insertion of Inhbb into the Inhba locus rescues the Inhba-null phenotype and reveals new activin functions. Nat. Genet. 2000, 25:453-457.
19. Brunner A.M., Marquardt H., Malacko A.R., Lioubin M.N., Purchio A.F. Site-directed mutagenesis of cysteine residues in the pro region of the transforming growth factor beta 1 precursor. Expression and characterization of mutant proteins. J. Biol. Chem. 1989, 264:13660-13664.
20. Cheifetz S., Ling N., Guillemin R., Massague J. A surface component on GH3 pituitary cells that recognizes transforming growth factor-beta, activin, and inhibin. J. Biol. Chem. 1988, 263:17225-17228.
21. Cheifetz S., Massague J. Transforming growth factor-beta (TGF-beta) receptor proteoglycan. Cell surface expression and ligand binding in the absence of glycosaminoglycan chains. J. Biol. Chem. 1989, 264:12025-12028.
22. Cheifetz S., Hernandez H., Laiho M., ten Dijke P., Iwata K.K., Massague J. Distinct transforming growth factor-beta (TGF-beta) receptor subsets as determinants of cellular responsiveness to three TGF-beta isoforms. J. Biol. Chem. 1990, 265:20533-20538.
23. Ciarmela P., Florio P., Toti P., Franchini A., Maguer-Satta V., Ginanneschi C., Ottaviani E., Petraglia F. Human placenta and fetal membranes express follistatin-related gene mRNA and protein. J. Endocrinol. Invest. 2003, 26:641-645.
24. Daopin S., Piez K.A., Ogawa Y., Davies D.R. Crystal structure of transforming growth factor-beta 2: an unusual fold for the superfamily. Science 1992, 257:369-373.
25. del Re E., Sidis Y., Fabrizio D.A., Lin H.Y., Schneyer A. Reconstitution and analysis of soluble inhibin and activin receptor complexes in a cell-free system. J. Biol. Chem. 2004, 279:53126-53135.
26. Donaldson C.J., Mathews L.S., Vale W.W. Molecular cloning and binding properties of the human type II activin receptor. Biochem. Biophys. Res. Commun. 1992, 184:310-316.
27. Esparza-Lopez J., Montiel J.L., Vilchis-Landeros M.M., Okadome T., Miyazono K., Lopez-Casillas F. Ligand binding and functional properties of betaglycan, a co-receptor of the transforming growth factor-beta superfamily. Specialized binding regions for transforming growth factor-beta and inhibin A. J. Biol. Chem. 2001, 276:14588-14596.
28. Farnworth P.G., Harrison C.A., Leembruggen P., Chan K.L., Stanton P.G., Ooi G.T., Rahman N.A., Huhtaniemi I.T., Findlay J.K., Robertson D.M. Inhibin binding sites and proteins in pituitary, gonadal, adrenal and bone cells. Mol. Cell. Endocrinol. 2001, 180:63-71.
29. Ferguson C.A., Tucker A.S., Christensen L., Lau A.L., Matzuk M.M., Sharpe P.T. Activin is an essential early mesenchymal signal in tooth development that is required for patterning of the murine dentition. Genes Dev. 1998, 12:2636-2649.
30. Florio P., Ciarmela P., Toti P., Maguer-Satta V., Rimokh R., Buonocore G., Rossi M., Gioffre W., Petraglia F. Human endometrium and decidua express follistatin-related gene (FLRG) mRNA and peptide. Mol. Cell. Endocrinol. 2004, 218:129-135.
31. Fukushima D., Butzow R., Hildebrand A., Ruoslahti E. Localization of transforming growth factor beta binding site in betaglycan. Comparison with small extracellular matrix proteoglycans. J. Biol. Chem. 1993, 268:22710-22715.
32. Ge G., Hopkins D.R., Ho W.B., Greenspan D.S. GDF11 forms a bone morphogenetic protein 1-activated latent complex that can modulate nerve growth factor-induced differentiation of PC12 cells. Mol. Cell. Biol. 2005, 25:5846-5858.
33. Gray A.M., Mason A.J. Requirement for activin A and transforming growth factor-beta 1 pro-regions in homodimer assembly. Science 1990, 247:1328-1330.
34. Gray P.C., Greenwald J., Blount A.L., Kunitake K.S., Donaldson C.J., Choe S., Vale W. Identification of a binding site on the type II activin receptor for activin and inhibin. J. Biol. Chem. 2000, 275:3206-3212.
35. Greenwald J., Fischer W.H., Vale W.W., Choe S. Three-finger toxin fold for the extracellular ligand-binding domain of the type II activin receptor serine kinase. Nat. Struct. Biol. 1999, 6:18-22.
36. Greenwald J., Groppe J., Gray P., Wiater E., Kwiatkowski W., Vale W., Choe S. The BMP7/ActRII extracellular domain complex provides new insights into the cooperative nature of receptor assembly. Mol. Cell 2003, 11:605-617.
37. Greenwald J., Vega M.E., Allendorph G.P., Fischer W.H., Vale W., Choe S. A flexible activin explains the membrane-dependent cooperative assembly of TGF-beta family receptors. Mol. Cell 2004, 15:485-489.
38. Griffith D.L., Keck P.C., Sampath T.K., Rueger D.C., Carlson W.D. Three-dimensional structure of recombinant human osteogenic protein 1: structural paradigm for the transforming growth factor beta superfamily. Proc. Natl. Acad. Sci. USA 1996, 93:878-883.
39. Groppe J., Hinck C.S., Samavarchi-Tehrani P., Zubieta C., Schuermann J.P., Taylor A.B., Schwarz P.M., Wrana J.L., Hinck A.P. Cooperative assembly of TGF-beta superfamily signaling complexes is mediated by two disparate mechanisms and distinct modes of receptor binding. Mol. Cell 2008, 29:157-168.
40. Han S., Loulakis P., Griffor M., Xie Z. Crystal structure of activin receptor type IIB kinase domain from human at 2.0 Angstrom resolution. Protein Sci. 2007, 16:2272-2277.
41. Handler M., Yurchenco P.D., Iozzo R.V. Developmental expression of perlecan during murine embryogenesis. Dev. Dyn. 1997, 210:130-145.
42. Harrington A.E., Morris-Triggs S.A., Ruotolo B.T., Robinson C.V., Ohnuma S., Hyvonen M. Structural basis for the inhibition of activin signalling by follistatin. EMBO J. 2006, 25:1035-1045.
43. Harrison C.A., Gray P.C., Koerber S.C., Fischer W., Vale W. Identification of a functional binding site for activin on the type I receptor ALK4. J. Biol. Chem. 2003, 278:21129-21135.
44. Harrison C.A., Gray P.C., Fischer W.H., Donaldson C., Choe S., Vale W. An activin mutant with disrupted ALK4 binding blocks signaling via type II receptors. J. Biol. Chem. 2004, 279:28036-28044.
45. Harrison C.A., Chan K.L., Robertson D.M. Activin-A binds follistatin and type II receptors through overlapping binding sites: generation of mutants with isolated binding activities. Endocrinology 2006, 147:2744-2753.
46. Hashimoto O., Nakamura T., Shoji H., Shimasaki S., Hayashi Y., Sugino H. A novel role of follistatin, an activin-binding protein, in the inhibition of activin action in rat pituitary cells. Endocytotic degradation of activin and its acceleration by follistatin associated with cell-surface heparan sulfate. J. Biol. Chem. 1997, 272:13835-13842.
47. Hashimoto O., Kawasaki N., Tsuchida K., Shimasaki S., Hayakawa T., Sugino H. Difference between follistatin isoforms in the inhibition of activin signalling: activin neutralizing activity of follistatin isoforms is dependent on their affinity for activin. Cell. Signal. 2000, 12:565-571.
48. Hayette S., Gadoux M., Martel S., Bertrand S., Tigaud I., Magaud J.P., Rimokh R. FLRG (follistatin-related gene), a new target of chromosomal rearrangement in malignant blood disorders. Oncogene 1998, 16:2949-2954.
49. Hill J.J., Davies M.V., Pearson A.A., Wang J.H., Hewick R.M., Wolfman N.M., Qiu Y. The myostatin propeptide and the follistatin-related gene are inhibitory binding proteins of myostatin in normal serum. J. Biol. Chem. 2002, 277:40735-40741.
50. Husken-Hindi P., Tsuchida K., Park M., Corrigan A.Z., Vaughan J.M., Vale W.W., Fischer W.H. Monomeric activin A retains high receptor binding affinity but exhibits low biological activity. J. Biol. Chem. 1994, 269:19380-19384.
51. Inouye S., Ling N., Shimasaki S. Localization of the heparin binding site of follistatin. Mol. Cell. Endocrinol. 1992, 90:1-6.
52. Jazwinska A., Badakov R., Keating M.T. Activin-betaA signaling is required for zebrafish fin regeneration. Curr. Biol. 2007, 17:1390-1395.
53. Kelber J.A., Shani G., Booker E.C., Vale W.W., Gray P.C. Cripto is a noncompetitive activin antagonist that forms analogous signaling complexes with activin and nodal. J. Biol. Chem. 2008, 283(8):4490-4500.
54. Kirsch T., Sebald W., Dreyer M.K. Crystal structure of the BMP-2-BRIA ectodomain complex. Nat. Struct. Biol. 2000, 7:492-496.
55. Lee S.J., McPherron A.C. Regulation of myostatin activity and muscle growth. Proc. Natl. Acad. Sci. USA 2001, 98(16):9306-9311.
56. Lee S.J., Reed L.A., Davies M.V., Girgenrath S., Goad M.E., Tomkinson K.N., Wright J.F., Barker C., Ehrmantraut G., Holmstrom J., Trowell B., Gertz B., Jiang M.S., Sebald S.M., Matzuk M., Li E., Liang L.F., Quattlebaum E., Stotish R.L., Wolfman N.M. Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc. Natl. Acad. Sci. USA 2005, 102(50):18117-18122.
57. Lewis K.A., Gray P.C., Blount A.L., MacConell L.A., Wiater E., Bilezikjian L.M., Vale W. Betaglycan binds inhibin and can mediate functional antagonism of activin signalling. Nature 2000, 404:411-414.
58. Li Q., Kumar R., Underwood K., O'Connor A.E., Loveland K.L., Seehra J.S., Matzuk M.M. Prevention of cachexia-like syndrome development and reduction of tumor progression in inhibin-deficient mice following administration of a chimeric activin receptor type II-murine Fc protein. Mol. Hum. Reprod. 2007, 13:675-683.
59. Li S., Shimono C., Norioka N., Nakano I., Okubo T., Yagi Y., Hayashi M., Sato Y., Fujisaki H., Hattori S., Sugiura N., Kimata K., Sekiguchi K. Activin A binds to perlecan through its pro-region that has heparin/heparan sulfate binding activity. J. Biol. Chem. 2010, 285:36645-36655.
60. Lopez-Casillas F., Cheifetz S., Doody J., Andres J.L., Lane W.S., Massague J. Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-beta receptor system. Cell 1991, 67:785-795.
61. Lopez-Casillas F., Wrana J.L., Massague J. Betaglycan presents ligand to the TGF beta signaling receptor. Cell 1993, 73:1435-1444.
62. Lopez-Casillas F., Payne H.M., Andres J.L., Massague J. Betaglycan can act as a dual modulator of TGF-beta access to signaling receptors: mapping of ligand binding and GAG attachment sites. J. Cell Biol. 1994, 124:557-568.
63. Lotinun S., Pearsall R.S., Davies M.V., Marvell T.H., Monnell T.E., Ucran J., Fajardo R.J., Kumar R., Underwood K.W., Seehra J., Bouxsein M.L., Baron R. A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys. Bone 2010, 46:1082-1088.
64. Macri L., Silverstein D., Clark R.A. Growth factor binding to the pericellular matrix and its importance in tissue engineering. Adv. Drug Deliv. Rev. 2007, 59:1366-1381.
65. Makanji Y., Harrison C.A., Stanton P.G., Krishna R., Robertson D.M. Inhibin A and B in vitro bioactivities are modified by their degree of glycosylation and their affinities to betaglycan. Endocrinology 2007, 148:2309-2316.
66. Makanji Y., Walton K.L., Wilce M.C., Chan K.L., Robertson D.M., Harrison C.A. Suppression of inhibin A biological activity by alterations in the binding site for betaglycan. J. Biol. Chem. 2008, 283:16743-16751.
67. Makanji Y., Temple-Smith P.D., Walton K.L., Harrison C.A., Robertson D.M. Inhibin B is a more potent suppressor of rat follicle-stimulating hormone release than inhibin a in vitro and in vivo. Endocrinology 2009, 150:4784-4793.
68. Manabe R., Tsutsui K., Yamada T., Kimura M., Nakano I., Shimono C., Sanzen N., Furutani Y., Fukuda T., Oguri Y., Shimamoto K., Kiyozumi D., Sato Y., Sado Y., Senoo H., Yamashina S., Fukuda S., Kawai J., Sugiura N., Kimata K., Hayashizaki Y., Sekiguchi K. Transcriptome-based systematic identification of extracellular matrix proteins. Proc. Natl. Acad. Sci. USA 2008, 105:12849-12854.
69. Mason A.J., Farnworth P.G., Sullivan J. Characterization and determination of the biological activities of noncleavable high molecular weight forms of inhibin A and activin A. Mol. Endocrinol. 1996, 10:1055-1065.
70. Massague J., Seoane J., Wotton D. Smad transcription factors. Genes Dev. 2005, 19:2783-2810.
71. Mathews L.S., Vale W.W. Expression cloning of an activin receptor, a predicted transmembrane serine kinase. Cell 1991, 65:973-982.
72. Mathews L.S., Vale W.W., Kintner C.R. Cloning of a second type of activin receptor and functional characterization in Xenopus embryos. Science 1992, 255:1702-1705.
73. Mathews L.S., Vale W.W. Characterization of type II activin receptors. Binding, processing, and phosphorylation. J. Biol. Chem. 1993, 268:19013-19018.
74. Matsuzaki K., Xu J., Wang F., McKeehan W.L., Krummen L., Kan M. A widely expressed transmembrane serine/threonine kinase that does not bind activin, inhibin, transforming growth factor beta, or bone morphogenic factor. J. Biol. Chem. 1993, 268:12719-12723.
75. Matzuk M.M., Finegold M.J., Su J.G., Hsueh A.J., Bradley A. Alpha-inhibin is a tumour-suppressor gene with gonadal specificity in mice. Nature 1992, 360:313-319.
76. Matzuk M.M., Finegold M.J., Mather J.P., Krummen L., Lu H., Bradley A. Development of cancer cachexia-like syndrome and adrenal tumors in inhibin-deficient mice. Proc. Natl. Acad. Sci. USA 1994, 91:8817-8821.
77. Mendoza V., Vilchis-Landeros M.M., Mendoza-Hernandez G., Huang T., Villarreal M.M., Hinck A.P., Lopez-Casillas F., Montiel J.L. Betaglycan has two independent domains required for high affinity TGF-beta binding: proteolytic cleavage separates the domains and inactivates the neutralizing activity of the soluble receptor. Biochemistry 2009, 48:11755-11765.
78. Michel U., Rao A., Findlay J.K. Rat follistatin: ontogeny of steady-state mRNA levels in different tissues predicts organ-specific functions. Biochem. Biophys. Res. Commun. 1991, 180:223-230.
79. Moren A., Ichijo H., Miyazono K. Molecular cloning and characterization of the human and porcine transforming growth factor-beta type III receptors. Biochem. Biophys. Res. Commun. 1992, 189:356-362.
80. Murdoch A.D., Liu B., Schwarting R., Tuan R.S., Iozzo R.V. Widespread expression of perlecan proteoglycan in basement membranes and extracellular matrices of human tissues as detected by a novel monoclonal antibody against domain III and by in situ hybridization. J. Histochem. Cytochem. 1994, 42:239-249.
81. Nakamura T., Takio K., Eto Y., Shibai H., Titani K., Sugino H. Activin-binding protein from rat ovary is follistatin. Science 1990, 247:836-838.
82. Nakamura T., Sugino K., Titani K., Sugino H. Follistatin, an activin-binding protein, associates with heparan sulfate chains of proteoglycans on follicular granulosa cells. J. Biol. Chem. 1991, 266:19432-19437.
83. Nakayama K. Furin: a mammalian subtilisin/Kex2p-like endoprotease involved in processing of a wide variety of precursor proteins. Biochem. J. 1997, 327(Pt 3):625-635.
84. Otsuka F., Moore R.K., Iemura S., Ueno N., Shimasaki S. Follistatin inhibits the function of the oocyte-derived factor BMP-15. Biochem. Biophys. Res. Commun. 2001, 289(5):961-966.
85. Patthy L., Nikolics K. Functions of agrin and agrin-related proteins. Trends Neurosci. 1993, 16:76-81.
86. Pepin M.C., Beauchemin M., Collins C., Plamondon J., O'Connor-McCourt M.D. Mutagenesis analysis of the membrane-proximal ligand binding site of the TGF-beta receptor type III extracellular domain. FEBS Lett. 1995, 377:368-372.
87. Phillips D.J., de Kretser D.M. Follistatin: a multifunctional regulatory protein. Front. Neuroendocrinol. 1998, 19:287-322.
88. Radaev S., Zou Z., Huang T., Lafer E.M., Hinck A.P., Sun P.D. Ternary complex of transforming growth factor-beta1 reveals isoform-specific ligand recognition and receptor recruitment in the superfamily. J. Biol. Chem. 2010, 285:14806-14814.
89. Rebbapragada A., Benchabane H., Wrana J.L., Celeste A.J., Attisano L. Myostatin signals through a transforming growth factor beta-like signaling pathway to block adipogenesis. Mol. Cell. Biol. 2003, 23(20):7230-7242.
90. Rees B., Bilwes A. Three-dimensional structures of neurotoxins and cardiotoxins. Chem. Res. Toxicol. 1993, 6:385-406.
91. Reissmann E., Jörnvall H., Blokzijl A., Andersson O., Chang C., Minchiotti G., Persico M.G., Ibáñez C.F., Brivanlou A.H. The orphan receptor ALK7 and the Activin receptor ALK4 mediate signaling by Nodal proteins during vertebrate development. Genes Dev. 2001, 15(15):2010-2022.
92. Rodino-Klapac L.R., Haidet A.M., Kota J., Handy C., Kaspar B.K., Mendell J.R. Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease. Muscle Nerve 2009, 39:283-296.
93. Sako D., Grinberg A.V., Liu J., Davies M.V., Castonguay R., Maniatis S., Andreucci A.J., Pobre E.G., Tomkinson K.N., Monnell T.E., Ucran J.A., Martinez-Hackert E., Pearsall R.S., Underwood K.W., Seehra J., Kumar R. Characterization of the ligand binding functionality of the extracellular domain of activin receptor type IIb. J. Biol. Chem 2010, 285(27):21037-21048.
94. Schlunegger M.P., Grutter M.G. An unusual feature revealed by the crystal structure at 2.2 A resolution of human transforming growth factor-beta 2. Nature 1992, 358:430-434.
95. Schneyer A., Tortoriello D., Sidis Y., Keutmann H., Matsuzaki T., Holmes W. Follistatin-related protein (FSRP): a new member of the follistatin gene family. Mol. Cell. Endocrinol. 2001, 180:33-38.
96. Schneyer A., Schoen A., Quigg A., Sidis Y. Differential binding and neutralization of activins A and B by follistatin and follistatin like-3 (FSTL-3/FSRP/FLRG). Endocrinology 2003, 144:1671-1674.
97. Schrewe H., Gendron-Maguire M., Harbison M.L., Gridley T. Mice homozygous for a null mutation of activin beta B are viable and fertile. Mech. Dev. 1994, 47:43-51.
98. Sengle, G., Ono, R.N., Sasaki, T., Sakai, L.Y., 2010. Prodomains of transforming growth factor {beta} (TGF{beta}) superfamily members specify different functions:Extracellular matrix interactions and growth factor bioavailability. J. Biol. Chem.
99. Shimasaki S., Koga M., Esch F., Cooksey K., Mercado M., Koba A., Ueno N., Ying S.Y., Ling N., Guillemin R. Primary structure of the human follistatin precursor and its genomic organization. Proc. Natl. Acad. Sci. USA 1988, 85:4218-4222.
100. Sidis Y., Tortoriello D.V., Holmes W.E., Pan Y., Keutmann H.T., Schneyer A.L. Follistatin-related protein and follistatin differentially neutralize endogenous vs. exogenous activin. Endocrinology 2002, 143:1613-1624.
101. Sidis Y., Schneyer A.L., Keutmann H.T. Heparin and activin-binding determinants in follistatin and FSTL3. Endocrinology 2005, 146:130-136.
102. Sidis Y., Mukherjee A., Keutmann H., Delbaere A., Sadatsuki M., Schneyer A. Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins. Endocrinology 2006, 147:3586-3597.
103. Stamler R., Keutmann H.T., Sidis Y., Kattamuri C., Schneyer A., Thompson T.B. The structure of FSTL3.activin A complex. Differential binding of N-terminal domains influences follistatin-type antagonist specificity. J. Biol. Chem. 2008, 283:32831-32838.
104. Sugino K., Kurosawa N., Nakamura T., Takio K., Shimasaki S., Ling N., Titani K., Sugino H. Molecular heterogeneity of follistatin, an activin-binding protein. Higher affinity of the carboxyl-terminal truncated forms for heparan sulfate proteoglycans on the ovarian granulosa cell. J. Biol. Chem. 1993, 268:15579-15587.
105. Suszko M.I., Balkin D.M., Chen Y., Woodruff T.K. Smad3 mediates activin-induced transcription of follicle-stimulating hormone beta-subunit gene. Mol. Endocrinol. 2005, 19:1849-1858.
106. Takehara-Kasamatsu Y., Tsuchida K., Nakatani M., Murakami T., Kurisaki A., Hashimoto O., Ohuchi H., Kurose H., Mori K., Kagami S., Noji S., Sugino H. Characterization of follistatin-related gene as a negative regulatory factor for activin family members during mouse heart development. J. Med. Invest. 2007, 54:276-288.
107. ten Dijke P., Ichijo H., Franzen P., Schulz P., Saras J., Toyoshima H., Heldin C.H., Miyazono K. Activin receptor-like kinases: a novel subclass of cell-surface receptors with predicted serine/threonine kinase activity. Oncogene 1993, 8:2879-2887.
108. ten Dijke P., Hill C.S. New insights into TGF-beta-Smad signalling. Trends Biochem. Sci. 2004, 29:265-273.
109. Thies R.S., Chen T., Davies M.V., Tomkinson K.N., Pearson A.A., Shakey Q.A., Wolfman N.M. GDF-8 propeptide binds to GDF-8 and antagonizes biological activity by inhibiting GDF-8 receptor binding. Growth Factors 2001, 18:251-259.
110. Thompson T.B., Woodruff T.K., Jardetzky T.S. Structures of an ActRIIB:activin A complex reveal a novel binding mode for TGF-beta ligand:receptor interactions. EMBO J. 2003, 22:1555-1566.
111. Thompson T.B., Lerch T.F., Cook R.W., Woodruff T.K., Jardetzky T.S. The structure of the follistatin:activin complex reveals antagonism of both type I and type II receptor binding. Dev. Cell 2005, 9:535-543.
112. Tsuchida K., Sawchenko P.E., Nishikawa S., Vale W.W. Molecular cloning of a novel type I receptor serine/threonine kinase for the TGF beta superfamily from rat brain. Mol. Cell. Neurosci. 1996, 7:467-478.
113. Tsuchida K., Arai K.Y., Kuramoto Y., Yamakawa N., Hasegawa Y., Sugino H. Identification and characterization of a novel follistatin-like protein as a binding protein for the TGF-beta family. J. Biol. Chem. 2000, 275:40788-40796.
114. Tsuchida K., Nakatani M., Yamakawa N., Hashimoto O., Hasegawa Y., Sugino H. Activin isoforms signal through type I receptor serine/threonine kinase ALK7. Mol. Cell. Endocrinol. 2004, 220:59-65.
115. Tsuchida K., Nakatani M., Uezumi A., Murakami T., Cui X. Signal transduction pathway through activin receptors as a therapeutic target of musculoskeletal diseases and cancer. Endocr. J. 2008, 55:11-21.
116. Tuuri T., Eramaa M., Hilden K., Ritvos O. The tissue distribution of activin beta A- and beta B-subunit and follistatin messenger ribonucleic acids suggests multiple sites of action for the activin-follistatin system during human development. J. Clin. Endocrinol. Metab. 1994, 78:1521-1524.
117. Vale W., Rivier J., Vaughan J., McClintock R., Corrigan A., Woo W., Karr D., Spiess J. Purification and characterization of an FSH releasing protein from porcine ovarian follicular fluid. Nature 1986, 321:776-779.
118. Vassalli A., Matzuk M.M., Gardner H.A., Lee K.F., Jaenisch R. Activin/inhibin beta B subunit gene disruption leads to defects in eyelid development and female reproduction. Genes Dev. 1994, 8:414-427.
119. Vilchis-Landeros M.M., Montiel J.L., Mendoza V., Mendoza-Hernandez G., Lopez-Casillas F. Recombinant soluble betaglycan is a potent and isoform-selective transforming growth factor-beta neutralizing agent. Biochem. J. 2001, 355:215-222.
120. Vitt U.A., Hsu S.Y., Hsueh A.J. Evolution and classification of cystine knot-containing hormones and related extracellular signaling molecules. Mol. Endocrinol. 2001, 15:681-694.
121. Walton K.L., Makanji Y., Wilce M.C., Chan K.L., Robertson D.M., Harrison C.A. A common biosynthetic pathway governs the dimerization and secretion of inhibin and related transforming growth factor beta (TGFbeta) ligands. J. Biol. Chem. 2009, 284:9311-9320.
122. Walton K.L., Makanji Y., Chen J., Wilce M.C., Chan K.L., Robertson D.M., Harrison C.A. Two distinct regions of latency associated peptide coordinate stability of the latent TGF-β1 complex. J. Biol. Chem. 2010, 285(22):17029-17037.
123. Wankell M., Kaesler S., Zhang Y.Q., Florence C., Werner S., Duan R. The activin binding proteins follistatin and follistatin-related protein are differentially regulated in vitro and during cutaneous wound repair. J. Endocrinol. 2001, 171:385-395.
124. Weber D., Kotzsch A., Nickel J., Harth S., Seher A., Mueller U., Sebald W., Mueller T.D. A silent H-bond can be mutationally activated for high-affinity interaction of BMP-2 and activin type IIB receptor. BMC Struct. Biol. 2007, 7:6.
125. Welt C., Sidis Y., Keutmann H., Schneyer A. Activins, inhibins, and follistatins: from endocrinology to signaling. A paradigm for the new millennium. Exp. Biol. Med. (Maywood) 2002, 227:724-752.
126. Wiater E., Harrison C.A., Lewis K.A., Gray P.C., Vale W.W. Identification of distinct inhibin and transforming growth factor beta-binding sites on betaglycan: functional separation of betaglycan co-receptor actions. J. Biol. Chem. 2006, 281:17011-17022.
127. Wiater E., Lewis K.A., Donaldson C., Vaughan J., Bilezikjian L., Vale W. Endogenous betaglycan is essential for high-potency inhibin antagonism in gonadotropes. Mol. Endocrinol. 2009, 23:1033-1042.
128. Wrana J.L., Attisano L., Carcamo J., Zentella A., Doody J., Laiho M., Wang X.F., Massague J. TGF beta signals through a heteromeric protein kinase receptor complex. Cell 1992, 71:1003-1014.
129. Wuytens G., Verschueren K., de Winter J.P., Gajendran N., Beek L., Devos K., Bosman F., de Waele P., Andries M., van Raaij A.J., Smith J.C., Huylebroeck D. Identification of two amino acids in activin A that are important for biological activity and binding to the activin type II receptors. J. Biol. Chem. 1999, 274:9821-9827.
130. Xia Y., Sidis Y., Schneyer A. Overexpression of follistatin-like 3 in gonads causes defects in gonadal development and function in transgenic mice. Mol. Endocrinol. 2004, 18:979-994.
131. Zhou X., Wang J.L., Lu J., Song Y., Kwak K.S., Jiao Q., Rosenfeld R., Chen Q., Boone T., Simonet W.S., Lacey D.L., Goldberg A.L., Han H.Q. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 2010, 142:531-543.